1
|
Tang Y, Zhao J, Suo H, Hu C, Li Q, Li G, Han S, Su X, Song W, Jin M, Li Y, Li S, Wei L, Jiang X, Jiang S. Sinigrin reduces the virulence of Staphylococcus aureus by targeting coagulase. Microb Pathog 2024; 194:106841. [PMID: 39117013 DOI: 10.1016/j.micpath.2024.106841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Revised: 07/26/2024] [Accepted: 08/03/2024] [Indexed: 08/10/2024]
Abstract
Multi-resistant Staphylococcus aureus (S. aureus) infection is a significant global health concern owing to its high mortality and morbidity rates. Coagulase (Coa), a key enzyme that activates prothrombin to initiate host coagulation, has emerged as a promising target for anti-infective therapeutic approaches. This study identified sinigrin as a potent Coa inhibitor that significantly inhibited S. aureus-induced coagulation at concentration as low as 32 mg/L. Additionally, at a higher concentration of 128 mg/L, sinigrin disrupted the self-protection mechanism of S. aureus. Thermal shift and fluorescence-quenching assays confirmed the direct binding of sinigrin to the Coa protein. Molecular docking analysis predicted specific binding sites for sinigrin in the Coa molecule, and point mutation experiments highlighted the importance of Arg-187 and Asp-222 as critical binding sites for both Coa and sinigrin. In vivo studies demonstrated that the combination of sinigrin with oxacillin exhibited greater antibacterial efficacy than oxacillin alone in the treatment of S. aureus-induced pneumonia in mice. Furthermore, sinigrin was shown to reduce bacterial counts and inflammatory cytokine levels in the lung tissues of S. aureus-infected mice. In summary, sinigrin was shown to directly target Coa, resulting in the attenuation of S. aureus virulence, which suggests the potential of sinigrin as an adjuvant for future antimicrobial therapies.
Collapse
Affiliation(s)
- Yating Tang
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Jingming Zhao
- Proctology Department, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Huiqin Suo
- School of Pharmacy, Changchun University of Traditional Chinese Medicine, Changchun, 130117, China
| | - Chunjie Hu
- Proctology Department, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Qingjie Li
- PhD Research Center of Traditional Chinese Medicine, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Guofeng Li
- Proctology Department, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130021, China
| | - Shaoyu Han
- The University of Queensland, St Lucia, QLD, 4067, China
| | - Xin Su
- School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Wu Song
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Mengli Jin
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Yufen Li
- School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China
| | - Songyang Li
- School of Pharmacy, Changchun University of Traditional Chinese Medicine, Changchun, 130117, China
| | - Lin Wei
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, 130117, China.
| | - Xin Jiang
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, 130117, China; School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China.
| | - Shuang Jiang
- Clinical Medical College, Changchun University of Chinese Medicine, Changchun, 130117, China.
| |
Collapse
|
2
|
Kane TL, Carothers KE, Lee SW. Virulence Factor Targeting of the Bacterial Pathogen Staphylococcus aureus for Vaccine and Therapeutics. Curr Drug Targets 2018; 19:111-127. [PMID: 27894236 PMCID: PMC5957279 DOI: 10.2174/1389450117666161128123536] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Revised: 10/12/2016] [Accepted: 10/27/2016] [Indexed: 12/21/2022]
Abstract
BACKGROUND Staphylococcus aureus is a major bacterial pathogen capable of causing a range of infections in humans from gastrointestinal disease, skin and soft tissue infections, to severe outcomes such as sepsis. Staphylococcal infections in humans can be frequent and recurring, with treatments becoming less effective due to the growing persistence of antibiotic resistant S. aureus strains. Due to the prevalence of antibiotic resistance, and the current limitations on antibiotic development, an active and highly promising avenue of research has been to develop strategies to specifically inhibit the activity of virulence factors produced S. aureus as an alternative means to treat disease. OBJECTIVE In this review we specifically highlight several major virulence factors produced by S. aureus for which recent advances in antivirulence approaches may hold promise as an alternative means to treating diseases caused by this pathogen. Strategies to inhibit virulence factors can range from small molecule inhibitors, to antibodies, to mutant and toxoid forms of the virulence proteins. CONCLUSION The major prevalence of antibiotic resistant strains of S. aureus combined with the lack of new antibiotic discoveries highlight the need for vigorous research into alternative strategies to combat diseases caused by this highly successful pathogen. Current efforts to develop specific antivirulence strategies, vaccine approaches, and alternative therapies for treating severe disease caused by S. aureus have the potential to stem the tide against the limitations that we face in the post-antibiotic era.
Collapse
Affiliation(s)
- Trevor L. Kane
- Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556
- Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN 46556, USA
| | - Katelyn E. Carothers
- Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556
- Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN 46556, USA
| | - Shaun W. Lee
- Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556
- Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN 46556, USA
| |
Collapse
|